Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes

• Status: Terminated
• Trial end date: 2021-01-13
• Target enrollment: 0
• Participant gender: All

Summary

Opioid analgesics are the most common postoperative pain medications used among dentists in the United States.Although these medications are highly effective in the postoperative dental pain management, not all patients optimally benefit from this therapy. Many suffer adverse consequences such as nausea, emesis, and psychomotor impairment, and there is a high prevalence of opioid prescription misuse among substance abusers within the dental patient population.

The use of non-opioid analgesics including ibuprofen and acetaminophen in the management of postoperative dental pain has demonstrated equivalent or superior analgesic effects compared to opioid analgesic therapies, typically with significantly less adverse effects.However, despite these results, dentists have encountered a high variability in the success of non-opioid analgesic responses among the postoperative dental pain population.Thus, new strategies for earlier recognition of analgesic responses for pain medications is fundamental in the field of dentistry. Therefore, this study will evaluate the clinical utility of pharmacogenomic testing in acute postoperative dental pain management among healthy adults who undergo extraction of impacted mandibular third molar.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Rochester
• Treatments: Acetaminophen; Ibuprofen; Oxycodone

Criteria

Inclusion Criteria:

• Patients who are able to read, comprehend, and sign the consent form, and willing to stay in the study unit for up to 12 hours.

• Patients who are reliable, cooperative, and of adequate intelligence to record the requested information on the questionnaire form(s).

• Women of childbearing potential who are not pregnant, as assessed by a urine pregnancy quick test on the day of the procedure, prior to surgery. Women must be using a method of birth control deemed acceptable by the investigator and continue to use this method during the duration of dosing with study medication

• Patient who develop sufficient levels of pain (rated at 50mm or more out of a 100 mm) on the DPIS within 6 hours post-surgical extraction.

• Patients who agree not to take analgesics other than protocol-defined rescue analgesics during the post-operative treatment period of 6 hours.

• Patients who agree to refrain from alcohol and sedative consumption during the post-operative period of 6 hours.

• Patients scheduled to undergo surgical removal of 3 or more impacted third molars, at least 1 of which must be a bony mandibular impaction. In addition, the sum of the dental impaction scores must be 9 or above, carried out by investigator.

Exclusion Criteria:

Subjects with:

• Known opioids and NSAIDs allergies (or induced asthmatic attacks)

• Known history of opioid abuse

• Recent history of gastrointestinal ulceration

• History of aspirin intolerance/cross-sensitivity

• Recent myocardial disease

• Uncontrolled hypertension

• Patients receiving anticoagulation therapy

• Uncontrolled diabetes

• Pregnant women

• Immunosuppression

• Recent history of opioid or NSAID therapies

• Subjects who do not achieve a qualifying baseline pain threshold of 50mm out of 100mm on the visual analog DIPS within 6 hours of completion of surgery